Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

What happened

Alamar Biosciences reported third-quarter 2026 revenue of $33.5 million, up 68% from the same quarter in 2025. It was selected by UK Biobank to profile 80,000 samples and began a 60,000-sample study with GSK. The company raised its 2026 revenue guidance to $121 million to $123 million.

Confirmed

Global impact / market context

Higher revenue and increased guidance suggest Alamar expects demand to support further growth. Biopharma customers became its largest revenue group for the first time, while the UK Biobank and GSK studies could expand use of its testing platform and create future revenue opportunities.

Analyst inference

The article describes both reported revenue growth and research projects, but gives no profit, cash available, or share-price information. The studies involve large sample counts, yet their financial contribution and timing are not stated, so revenue growth alone does not establish profitability.

Analyst inference

What to watch

1. Check future results against the raised 2026 revenue range of $121 million to $123 million, including whether growth continues beyond the reported third-quarter increase. Analyst inference
2. Watch for updates on the UK Biobank and GSK studies, including whether the planned sample profiling progresses and leads to additional paid work. Analyst inference
3. Look for later disclosures on profit and cash available, since the article reports revenue growth but provides no information on costs, earnings, or funding needs. Analyst inference

Evidence

• globenewswire.com